Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Sage Therapeutics Stock (NASDAQ: SAGE) stock price, news, charts, stock research, profile.
Open20.920 | Close20.580 |
Vol / Avg.760.121K / 1.722M | Mkt Cap1.232B |
Day Range20.300 - 20.980 | 52 Wk Range16.515 - 59.990 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -2.550 | -2.680 | -0.1300 | ||||
REV | 2.940M | 2.474M | -466.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-09-08 | B of A Securities | Tazeen Ahmad | Maintains | NeutralNeutral | Lowers | 25.00 | 24.00 |
2023-09-07 | Mizuho | Vamil Divan | Maintains | NeutralNeutral | Raises | 19.00 | 20.00 |
2023-09-07 | RBC Capital | Brian Abrahams | Maintains | Sector PerformSector Perform | Lowers | 25.00 | 22.00 |
2023-08-09 | Goldman Sachs | Salveen Richter | Maintains | NeutralNeutral | Lowers | 75.00 | 22.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
SAGE | Sage Therapeutics | -0.68% | 1.2B |
TWST | Twist Bioscience | -1.46% | 1.2B |
ETNB | 89bio | 0% | 1.2B |
ZNTL | Zentalis Pharma | 2.19% | 1.4B |
SNDX | Syndax Pharmaceuticals | 7.04% | 1.2B |
You can purchase shares of Sage Therapeutics (NASDAQ: SAGE) through any online brokerage.
Other companies in Sage Therapeutics’s space includes: Twist Bioscience (NASDAQ:TWST), 89bio (NASDAQ:ETNB), Zentalis Pharma (NASDAQ:ZNTL), Syndax Pharmaceuticals (NASDAQ:SNDX) and Day One Biopharmaceutical (NASDAQ:DAWN).
The latest price target for Sage Therapeutics (NASDAQ: SAGE) was reported by B of A Securities on Friday, September 8, 2023. The analyst firm set a price target for 24.00 expecting SAGE to rise to within 12 months (a possible 16.62% upside). 45 analyst firms have reported ratings in the last year.
The stock price for Sage Therapeutics (NASDAQ: SAGE) is $20.58 last updated September 29, 2023 at 8:20 PM UTC.
There is no dividend information for Sage Therapeutics.
Sage Therapeutics’s Q3 earnings are confirmed for Tuesday, November 7, 2023.
There is no upcoming split for Sage Therapeutics.
Sage Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.